Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 65 of 6351
-
New study aims to curb soldier suicides with remote coaching
Disease control Recruiting nowThis study evaluates the effectiveness of Pathfinding, a 6-month, remotely-delivered case management intervention designed to decrease suicidal behavior among active-duty Regular Army soldiers recently discharged from inpatient psychiatric treatment. Soldiers discharged from mili…
Sponsor: Uniformed Services University of the Health Sciences • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Triple threat: radiation, chemo, and immunotherapy before surgery shows promise for oral cancer
Disease control Not yet recruitingThe objective of this study is to evaluate the efficacy of neoadjuvant stereotactic body radiation therapy (SBRT) in combination with chemotherapy and immunotherapy, prior to radical surgery, in enhancing the 2-year event-free survival rate and overall survival rate in patients d…
Phase 3 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
New Dual-Targeting CAR-T therapy aims to outperform standard care in advanced myeloma
Disease control Recruiting nowThis is a randomised, multicentre, controlled, open-label, Phase III global study comparing the efficacy and safety of AZD0120 versus standard regimens (DKd \[daratumumab, carfilzomib, and dexamethasone\], DPd \[daratumumab, pomalidomide, and dexamethasone\], PVd \[pomalidomide, …
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
New mRNA vaccine against mpox enters key trial in africa
Vaccine Recruiting nowThis is a randomized, double-blind, placebo-controlled study which aims to assess the safety, reactogenicity, and immunogenicity after one and two doses of BNT166a or placebo in healthy participants.
Phase 2 • Sponsor: BioNTech SE • Aim: Vaccine
Last updated Aug 13, 2026 00:00 UTC
-
New combo treatment may spare head and neck cancer patients from disfiguring surgery
Disease control Recruiting nowThe NeoScorch HN study is a single institution multisite phase II trial including 3 cohorts of 25 patients each for patients with newly diagnosed locoregionally advanced, histologically confirmed, head and neck cancer eligible for curative-intent treatment, who will receive neo-a…
Phase 2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Could a late stroke drug give patients a second chance?
Disease control Recruiting nowThis study is open to adults who had an acute stroke caused by a clot blocking a blood vessel in the brain (acute ischemic stroke). This study is for people who had an acute stroke or woke up with a stroke and were last seen well more than 4.5 hours before joining the study. Part…
Phase 3 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
New drug targets genetic weakness in tough pancreatic cancer
Disease control Recruiting nowPancreatic cancer is difficult to diagnose early. By the time people have been diagnosed, the cancer has usually spread to other parts of the body (metastatic). The standard treatment is chemotherapy, but other treatments are needed to improve outcomes in people with pancreatic c…
Phase 3 • Sponsor: Astellas Pharma Global Development, Inc. • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
New drug combo aims to keep ovarian cancer at bay
Disease control Recruiting nowResearchers are looking for new ways to treat ovarian cancer (OC). Current treatment for OC may start with surgery to remove as much of the cancer as possible. After surgery, people may receive chemotherapy. After chemotherapy, standard care options may include: * Maintenance tr…
Phase 3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New Dual-Target CAR-T therapy takes on Hard-to-Treat myeloma
Disease control Not yet recruitingThis research project includes patients with relapsed/refractory multiple myeloma (r/r MM) who have received more than three lines of treatment, including those with secondary recurrence, SCT recurrence, and refractory cases. Through this study, we aim to preliminarily determine …
Sponsor: Donghua Zhang • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New combo aims to stop breast cancer return after chemo
Disease control Recruiting nowThis is a multi-center, open-lable, prospective, randomized phase III clinical trial to investigate the efficacy and safety of adjuvant ribociclib combined with aromatase inhibitor in hormone receptor-positive, HER2-negative early breast cancer with residual disease after neoadju…
Phase 3 • Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
New hope for advanced breast cancer: experimental drug combo enters phase 3 trial
Disease control Recruiting nowThis is a randomized, multicenter, open-label, phase 3 study evaluating the efficacy, safety, and tolerability of IBI354 combined with or without pertuzumab vs. THP as first-line treatment for HER2-positive unresectable, locally advanced or metastatic breast cancer.
Phase 3 • Sponsor: Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
Experimental T-Cell therapy takes on deadly brain virus
Disease control Recruiting nowThere is no approved standard treatment für progressive multifocal leukoencephalopathy (PML). The sponsor of the study is developing a new treatment. For this reason, the investigational medicinal product (IMP) called 'human allogenic HPyV-2-specific T cells' is to be tested in t…
Phase 2 • Sponsor: Hannover Medical School • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
New combo aims to control metastatic cancer in patients with limited spread
Disease control Recruiting nowThe combination of local consolidative therapy for oligometastases with systemic therapy offers the potential for clinical cure and significantly prolongs survival in a subset of patients with advanced metastatic disease. However, a considerable proportion of patients still do no…
Phase 3 • Sponsor: Ming-Yuan Chen • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Promising combo aims to boost Cancer-Free survival in head and neck cancer
Disease control Recruiting nowThis study is a randomized, open-label, multicenter phase III trial designed to systematically evaluate the efficacy and safety of perioperative neoadjuvant and adjuvant therapy with Becotatug vedotin in combination with PD-1 inhibitor versus PD-1 inhibitor alone in patients with…
Phase 3 • Sponsor: Ming-Yuan Chen • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
Could a pill save insulin cells? new trial for kids and young adults with type 1 diabetes
Disease control Recruiting nowThe purpose of this study is to find out if baricitinib can preserve beta-cell function in participants newly diagnosed with type 1 diabetes. Participation in the study will last about 60 weeks.
Phase 3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Heat, not surgery: new trial aims to cure thyroid cancer without a knife
Cure Recruiting nowThis pilot, single-arm clinical study evaluates the feasibility, safety, and effectiveness of radiofrequency ablation (RFA) as a curative treatment for small, low-risk papillary thyroid cancer (PTC). The study will enroll 30 adult patients (≥18 years) with biopsy-confirmed PTC me…
Sponsor: University Health Network, Toronto • Aim: Cure
Last updated Jun 27, 2026 12:35 UTC
-
Simple blood test could spot pancreatic cancer before symptoms start
Diagnosis Recruiting nowThis nationwide, multicenter, prospective, single-arm interventional feasibility study evaluates the Enzeavour Pancreatic Cancer assay in routine health checkups and cancer screening in Japan. Approximately 10,000 asymptomatic adults will be enrolled. Participants with an Enzeavo…
Sponsor: Cosomil, Inc. • Aim: Diagnosis
Last updated Jun 28, 2026 00:00 UTC
-
New hope for Tough-to-Treat myeloma: phase 3 trial launches
Disease control Recruiting nowThe purpose of this study is to evaluate how well JNJ-79635322 works when compared with an anti-B-cell maturation antigen (BCMA)xCD3 bispecific antibody.
Phase 3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
New targeted therapy combo aims to fight stubborn stomach cancers
Disease control Recruiting nowThe purpose of this study is to evaluate the efficacy and safety of sonesitatug vedotin in combination with capecitabine with or without rilvegostomig in first-line (1L) Claudin18.2 (CLDN18.2)-positive, human epidermal growth factor receptor 2 (HER2)-negative, gastric, gastroesop…
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Sep 10, 2026 03:00 UTC
-
HIV prevention breakthrough? Twice-Yearly shot could replace daily pills
Prevention Recruiting nowThe goal of this study is to learn how well long-acting lenacapavir works to prevent human immunodeficiency virus (HIV) infection in people at higher risk of getting HIV in Brazil. The study will also learn about safety, continued use over time, and whether people prefer this opt…
Sponsor: Oswaldo Cruz Foundation • Aim: Prevention
Last updated Jun 27, 2026 12:01 UTC